¿Cómo se comparó el EPS reciente de AGYTF con las expectativas?
¿Cómo fue el desempeño de los ingresos de Allergy Therapeutics PLC AGYTF en el último trimestre?
¿Cuál es la estimación de ingresos para Allergy Therapeutics PLC?
¿Cuál es la puntuación de calidad de ganancias de Allergy Therapeutics PLC?
¿Cuándo informa Allergy Therapeutics PLC sus ganancias?
¿Cuáles son las ganancias esperadas de Allergy Therapeutics PLC?
¿Superó Allergy Therapeutics PLC las expectativas de ganancias?
Estadísticas clave
Cierre Anterior
$0.11
Precio de apertura
$0.11
Rango del día
$0.11 - $0.11
Rango de 52 semanas
$0.052 - $0.11
Volumen
15.0K
Volumen promedio
241
EPS (TTM)
-0.01
Rendimiento de dividendos
--
Cap. de mercado
$675.5M
¿Qué es AGYTF?
Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company is headquartered in Worthing, West Sussex and currently employs 602 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. The company sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.